A key novel finding is the discovery that only AMKL cells with high PRMT1 expression drive leukemogenesis, and this PRMT1-driven leukemia can be effectively treated with the PRMT1 inhibitor MS023. The ...

BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESREMi faces competition from drugs like ruxolitinib, a ...

In mouse AML cells, some genes critical in leukemogenesis, including Myc, Meis1, and Runx2, are also super-enhancer-associated genes (8), which indicates that super-enhancers may dedicate to AML ...

HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation of $9.25 per share. This value is based on our estimates for successful ...

As mutated NPM1 (mNPM1) drives leukemogenesis through menin and the efficacy of menin inhibitors in producing treatment responses in mNPM1-associated AML, combination therapy using a VISTA ...

Induced pluripotent stem cells (iPSCs) originate from the reprogramming of adult somatic cells using four Yamanaka transcription factors. Since their discovery, the stem cell (SC) field achieved ...

1Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, China. 2Department of Hepatobiliary Surgery,Centre for Leading Medicine and Advanced Technologies of IHM, The First ...

University of P. J. Safarik in Kosice, Faculty of Sciences, Institute of Chemistry, Department of Physical Chemistry, Moyzesova 11, 041 01 Kosice, Slovakia ...

Objectives Recently, necroptosis has attracted increasing attention in arthritis research; however, it remains unclear whether its regulation is involved in osteoarthritis (OA) pathogenesis. Since ...